JIXING Announces the Grand Opening of the New Headquarter Office in China

A new start for a bright future

SHANGHAI, China, September 7, 2022 – Ji Xing Pharmaceuticals Limited (JIXING), a clinical-stage biopharmaceutical company committed to bringing innovative medicines to underserved Chinese patients with serious and life-threatening diseases, today announces the grand opening of its new headquarter office in China.

The new JIXING headquarter is located on the 22^nd Floor of the JC Plaza building at West Nanjing Road in Shanghai, covering an area of about 2200 square meters. The office is designed based on the ideas of innovation and collaboration. Through natural materials and light, ergonomic office furniture, open and flexible meeting spaces, the office creates a modern working environment and encourages communication and collaboration.

“As the founding CEO, I have experienced the growth journey of JIXING, from the business plan to the establishment of the company, to the first asset license-in, to the opening of the new headquarter office in China today. JIXING has grown into an innovation pioneer with full life cycle development capabilities and a solid pipeline of 7 novel assets in clinical stage targeting 9 indications in the cardiovascular and ophthalmology disease areas.” said Dr Peter Fong, Board Executive Director and CEO of JIXING. “The opening of the new headquarter office is a new start for our future growth. We are committed to continuing to expand the asset pipeline and drive our products’ commercialization so that patients can ultimately benefit from our innovation.”

"JIXING is a company driven by a sense of purpose and embedded in a diverse and inclusive culture. The opening of the new headquarter office in China will further enhance our competitiveness in talent attraction and retention, as well as building efficient and collaborative culture.” said Christine Dai, Chief HR Officer of JIXING. “We take great pride in our talents and corporate values and believe this is key to our sustainable development.”

JIXING entered a period of rapid growth in 2022 by obtaining one Breakthrough Therapy Designation, licensing-in two new products and initiationing three Phase 3 clinical trials in China. JIXING is actively establishing a commercial team to drive the commercialization of its growing product portfolio.